Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Lupin: Base effect mars performance - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Nov 19, 2004

    Lupin: Base effect mars performance

    Performance Summary
    Domestic pharma company, Lupin, announced dismal results in 2QFY05. While the topline has declined by 8.5%, the operating profit has declined at a faster rate of 60% YoY. The net profit however, has increased by about 20 times, which does not show the true picture, as this rise in profit is on back of some extraordinary expenses last year.

    (Rs m) 2QFY04 2QFY05 Change 1HFY04 1HFY05 Change
    Net sales 3,457 3,164 -8.5% 6,094 6,154 1.0%
    Total expenditure 2,679 2,839 6.0% 4,738 5,457 15.2%
    EBITDA 778 325 -58.3% 1,356 697 -48.6%
    EBITDA margin 22.5% 10.3%   22.2% 11.3%  
    Other income 83 12 -85.9% 127 51 -60.0%
    Interest expenses 150 62 -58.5% 309 133 -56.9%
    Depreciation 71 81 15.0% 140 160 14.5%
    Profit before tax 641 193 -69.9% 1,033 455 -56.0%
    Extraordinary items 509 -   509 -  
    Tax 123 18 -85.5% 235 73 -68.8%
    Profit after tax 9 175 1933.7% 289 381 31.8%
    Net profit margin 0.2% 5.5%   4.7% 6.2%  
    No. of shares 40 40   40 40  
    Diluted earnings per share* 0.9 17.4   14.4 19.0  
    P/E ratio (X)       44.9 34.0  

    About the company
    Lupin is a domestic pharma company with strong presence in cephalosporins and anti-TB segments (constituting more than 75% of the total sales in FY04). In the recent past, the company has managed to diversify its revenue mix (segment wise as well as geographically). About 50% of its revenues in FY04 were from international business. The company currently has 5 ANDA approvals with 13 filings and 21 DMF's with US FDA.

    What has driven performance in 2QFY05?
    High base effect: Net sales declined by 8.5% in the current quarter. The major reason for decline in sales was the base effect. The higher base in the same quarter last years was on account of the launch of Cefuroxime Axetil in the US generics space. Total revenues from this drug in FY04 was Rs 354 m. However, with competition increasing, there was a sharp fall in prices as well as loss of market share for Lupin. In the domestic market, retail sales grew by 13% YoY, while the overall growth in the Indian operations stood at 11%. In the quarter, the company launched 9 new products in the domestic market.

    Higher R&D and marketing expenses: The R&D expenses increased by 144% in the current quarter, driven by the company's focus on creating intellectual property. Besides, other expenses increased by 27% YoY with marketing and sales promotion constituting a major portion of this increase. During the quarter, company incurred Rs 73 m (2% of sales) towards sales promotion of one of its brands 'Suprax' in US.

    Cost Break up
      2QFY04 2QFY05 Change
    Raw material 1,632 1,408 -13.7%
    (as % of sales) 47.2% 44.5%  
    Staff cost 236 317 34.1%
    (as % of sales) 6.8% 10.0%  
    R&D expenditure 75 183 143.3%
    (as % of sales) 2.2% 5.8%  
    Other expenditure 736 932 26.6%
    (as % of sales) 21.3% 29.5%  
    Total 2,679 2,839 6.0%

    Net Profit falls: Net profit saw an increase of 20 times. However, this must be viewed with retrospect that the company has to shell out extraordinary expenses to the tune of Rs 509 m in the same quarter last year. If one excludes this effect, the net profit has actually declined by 66%. The tax provision has come down due to increased R&D expenses and sales from one its facilities, which has been granted EOU status (export oriented unit).

    What to expect?
    At Rs 645, the stock is trading at a price to earnings multiple of 34 times 1HFY05 earnings. Lupin is one of the strongest players in cepholosporins and anti-TB segment in the domestic market. Both these drugs involve complex technology of manufacturing, which suggest Lupin's strength in high technology front. New initiatives in increasing sales in the US generics market and the fermentation technology that company has are long-term positives. But the volatility in earnings is a cause of concern and to that extent, the risk profile is on the higher side.



    Equitymaster requests your view! Post a comment on "Lupin: Base effect mars performance". Click here!


    More Views on News

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

    May 29, 2017

    Currency fluctuation and one time provision impacts operating margins.

    Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 24, 2017 11:20 AM


    • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Financial Information With Charts